Itraconazole Injection.

Effects and efficacy:
For systemic onychomycosis, including systemic aspergillosis, candidiasis, diphasic fungal disease, and cryptococcosis. For fungal infections of the skin and subcutaneous tissue, including sporotrichosis, chromoblastomycosis, and aspergillosis. For fungal infections of the skin, hair, nail plate, and mucous membranes. For the treatment of oral and esophageal candidiasis in patients with HIV infection or a weakened immune system. For the prevention of invasive fungal infections in patients with hematologic tumors. Note: This product is not recommended for the initial treatment of life-threatening systemic fungal infections.
Usage and Dosage:
For oral administration of aspergillosis, 0.2g once a day for 2-5 months, adjusted according to clinical treatment effects; if it is invasive or disseminated aspergillosis, the dose is increased to 0.2g once a day. For intravenous administration, on the 1st and 2nd days, 200mg once a day, twice a day, each time drip for 1 hour; from the 3rd day onwards, 200mg once a day, each time drip for 1 hour. The safety of medication for more than 14 days is not clear. Please follow the doctor’s advice for details. For oral administration of candidiasis, 0.1-0.2g once a day, for 3 weeks to 7 months, and adjust according to the clinical treatment effect. For invasive and disseminated candidiasis, the dose is 0.2g once a day, twice a day. Please follow the doctor’s advice for details. For intravenous drip administration, refer to “Aspergillosis”. Please follow the doctor’s advice for details. For oral administration of blastomycosis, 0.1g once a day, or 0.2g once a day, twice a day, for 6 months. The duration of treatment is adjusted according to clinical efficacy. Please follow the doctor’s advice for details. For oral administration of histoplasmosis, 0.2g once a day, 1-2 times a day, for 8 months, and the duration of treatment is adjusted according to clinical efficacy. Please follow the doctor’s advice for details. For intravenous drip administration, refer to “Aspergillosis”. Please follow the doctor’s advice for details. For oral administration of paracoccidioidomycosis, 0.1g once a day, for 6 months, and the duration of treatment is adjusted according to clinical efficacy. Please follow your doctor’s advice for details. For intravenous administration of cryptococcosis, see “Aspergillosis”. Please follow your doctor’s advice for details. For oral administration of cutaneous lymphangiogenic sporotrichosis, 0.1g once a day for 3 consecutive months, and the duration of treatment is adjusted according to clinical efficacy. For oral administration of chromoblastomycosis, 0.1-0.2g once a day for 6 consecutive months, and the duration of treatment is adjusted according to clinical efficacy. Please follow your doctor’s advice for details. For empirical treatment of suspected systemic fungal infection in patients with febrile neutropenia, oral/intravenous sequential therapy: first intravenous drip, recommended 0.2g once, twice a day, after 4 doses, change to 0.2g once a day, for 14 consecutive days, then change to oral administration, 0.2g once, twice a day, until clinically significant neutropenia is relieved. Please follow your doctor’s advice for details. For oral administration of skin fungal diseases, 0.1g once a day for 15 consecutive days, or 0.2g once a day for 7 consecutive days. Please follow your doctor’s advice for details. For oral administration in highly keratinized areas, 0.1g once a day for 30 consecutive days, or 0.2g once a day for 7 consecutive days. Please follow the doctor’s advice for details. For oral administration in pityriasis versicolor and Malassezia folliculitis, 0.2g once a day for 7 consecutive days. Please follow the doctor’s advice for details. For oral administration in onychomycosis, shock therapy, 0.2g once a day, twice a day, the duration of a shock course is 1 week; continuous therapy, 0.2g once a day, once a day, for 3 consecutive months. Please follow the doctor’s advice for details. For oral administration in vulvovaginal candidiasis, 0.2g once a day, once a day, for 3 consecutive days; or 0.2g once a day, twice a day, only for 1 day. Please follow the doctor’s advice for details. For oral administration in fungal keratitis, 0.2g once a day, once a day, for 21 consecutive days. The duration of treatment is adjusted according to clinical efficacy. Please follow the doctor’s advice for details. For oral and esophageal candidiasis, 0.2g at a time, divided into 1-2 times, for 1 week; if ineffective after one week, continue for another week. Please follow the doctor’s advice for details. For oral administration to prevent invasive fungal infections, the oral solution is 5mg/kg per day, divided into 2 times. Please follow the doctor’s advice for details.
Adverse reactions:
Cardiovascular system: congestive heart failure, tachycardia, hypertension, edema. Skin: itching, rash, Stevens-Johnson syndrome. Gastrointestinal tract: abdominal pain, diarrhea, nausea, vomiting, necrotizing pancreatitis. Liver: elevated transaminase, hepatotoxicity. Nervous system: dizziness, headache. Respiratory system: pulmonary edema, upper respiratory tract infection, rhinitis, sinusitis. Note: This drug can cause dizziness, visual impairment and hearing loss. Avoid driving, operating instruments or other dangerous activities during medication.
Drug contraindications:
Allergic to this product is prohibited. It is prohibited during pregnancy. It is used with caution during lactation. It is used with caution in case of renal impairment. It is used with caution in driving. It is used with caution in case of liver impairment.